leadf
logo-loader
viewSareum Holdings PLC

Sareum Holdings says encouraged by conclusions from lupus study

An approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression

Sareum Holdings PLC -

Sareum Holdings PLC (LON:SAR), the specialist drug development company, has described results from studies of two of its small molecule inhibitors to combat lupus as “encouraging”.

The company, which is focused on delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, said that results have been published for its small molecule dual tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitors in disease model studies of systemic lupus erythematosus (SLE) by its collaborator, SRI International.

Sareum entered into a co-development agreement with SRI International in April 2013 to develop TYK2 inhibitors in autoimmune diseases. Sareum retains commercialisation rights for these and other TYK2 inhibitors.

The authors of the latest studies concluded that an approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression and may benefit numerous lupus patients in need of new options. They also noted that the results could influence treatments of other autoimmune diseases such as arthritis and psoriasis.

The TYK2/JAK1 inhibitor SAR-20351 (now known as SDC-1802) has been selected as a preclinical development candidate targeting cancer based on its overall profile that includes supportive data recently presented in October 2019 at the AACR-NCI-EORTC International Cancer Conference. Sareum is advancing a different TYK2/JAK1 inhibitor - SDC-1801 - as a preclinical candidate targeting autoimmune diseases.

"These data from studies using our small molecule TYK2/JAK1 inhibitors add to the body of evidence supporting this novel mechanism of action as a promising approach to treating autoimmune diseases such as SLE,” Tim Mitchell, the chief executive officer of Sareum said in a statement.

“Our own studies have also confirmed this potential in autoimmune diseases such as psoriasis and rheumatoid arthritis and we are delighted that this work indicates a possible application in lupus, which remains a condition with high unmet medical need,” he added.

Lupus is an autoimmune disease in which the body's immune system attacks healthy tissue in many parts of the body.

“This approach has also been recognised more broadly in the industry with several molecules targeting this pathway advancing through development. We look forward to reporting further progress as we advance our TYK2/JAK1 candidates through preclinical development,” Mitchell said.

Quick facts: Sareum Holdings PLC

Price: 2.287 GBX

AIM:SAR
Market: AIM
Market Cap: £72.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

on 12/8/20

2 min read